SEC Form 4 · accession 0001209191-17-020368
MERRIMACK PHARMACEUTICALS INC · MACK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael E Porter
Director
Period of report
Mar 10, 2017
Accepted (ET)
Mar 13, 2017 · 9:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001274792
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 10, 2017 | M | 85,000 | $2.69 | A | 839,448 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $2.69 | Mar 10, 2017 | M | 60,000 | D | — | Dec 8, 2020 | Common Stock | 60,000 | 0 | D |
| Stock Option (right to buy)F1 | $2.69 | Mar 10, 2017 | M | 25,000 | D | — | Oct 14, 2020 | Common Stock | 25,000 | 0 | D |
Explanation of responses
- F1This option is fully vested.